Imagine a “gene shredder” that doesn’t just cut DNA but consumes it like a game of Pac-Man. This is the core technology behind the work of Paul Garofalo and his company, Locus Biosciences, which is attempting to revitalize phage therapy—a century-old concept that has long struggled to compete with the efficiency of traditional antibiotics. While naturally occurring “wild type” phages often fail to fully eradicate infections, Locus is using genetic engineering to create precision-guided viruses that can wipe out specific bacterial pathogens without harming the body’s beneficial microbiome.

The company’s current efforts are focused on high-impact, difficult-to-treat conditions, most notably recurrent urinary tract infections (UTIs). By delivering a “cocktail” of six engineered phages via catheter and IV, they aim to move beyond mere symptom management toward a permanent cure for patients whose bodies have become colonized by stubborn bacteria. This approach represents a shift toward “precision medicine” for bacteria, moving away from the “scorched earth” policy of broad-spectrum antibiotics that often lead to systemic resistance and gut health devastation.

Looking further ahead, Garofalo envisions a world where phage therapy treats chronic inflammation and autoimmune disorders, such as Crohn’s disease. The hypothesis is that many systemic inflammatory issues are caused by non-transient “bad actor” bacteria that hide inside human cells—places where traditional antibiotics cannot reach. By engineering phages to penetrate these protective layers and eliminate the hidden triggers, the medical community could potentially shift from lifelong suppression of symptoms to actual curative treatments for a wide array of inflammatory diseases.

Surprising Insights

• Airport Wastewater Harvesting: To find the most diverse and effective phages, Locus samples wastewater from international airports, leveraging the fact that travelers bring a global biodiverse array of phages in their bodies.
• The “Gene Shredder” vs. “Scissors”: While most people know CRISPR as a tool for precise editing (scissors), Locus uses a variant called CRISPR-Cas3, which acts as a shredder to completely destroy bacterial DNA.
• The “Curse” of COVID Funding: Garofalo notes that the massive influx of capital into biotech during the pandemic created a “bolus of garbage ideas” and BS companies, which actually drained talent away from legitimate scientific breakthroughs for several years.
• PhD-Free Leadership: Garofalo attributes his company’s bias toward execution and his ability to ask “dumb” clarifying questions to the fact that he is a project manager by training rather than a PhD scientist.

Practical Takeaways

• Understand the Limits of Antibiotics: Recognize that broad-spectrum antibiotics can destroy the microbiome and are often unable to reach intracellular pathogens, which is why some infections keep recurring despite treatment.
• Advocate for Precision Medicine: If suffering from chronic, recurrent bacterial infections, stay informed about clinical trials involving phage therapy, as these are designed for the specific “colonization” patterns that traditional drugs miss.
• Focus on Root Causes over Suppression: When discussing long-term health with providers, consider the difference between “suppressing” an immune response (like with some autoimmune drugs) and “removing the trigger” (the bacterial cause) of inflammation.